Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

1.790 UNCHANGED
Streaming Delayed Price Updated: 2:48 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21
Open 1.790
Bid (Size) 1.730 (5)
Ask (Size) 1.880 (5)
Prev. Close 1.790
Today's Range 1.790 - 1.790
52wk Range 1.290 - 3.511
Shares Outstanding 78,986,490
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
From Innate Pharma SA
Via Business Wire

Performance

YTD
-4.3%
-4.3%
1 Month
-13.9%
-13.9%
3 Month
+4.7%
+4.7%
6 Month
-4.8%
-4.8%
1 Year
-16.7%
-16.7%

More News

Read More
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
From Innate Pharma SA
Via Business Wire
Outcome of Innate Pharma’s 2025 Annual General Meeting
From Innate Pharma SA
Via Business Wire
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
From Innate Pharma SA
Via Business Wire
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
From Innate Pharma SA
Via Business Wire
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
From Innate Pharma SA
Via Business Wire
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
From Innate Pharma SA
Via Business Wire
Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025
From Innate Pharma SA
Via Business Wire
Innate Pharma announces conference call and webcast for Q1 2025 business update
From Innate Pharma SA
Via Business Wire
Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F
From Innate Pharma SA
Via Business Wire
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
From Innate Pharma SA
Via Business Wire
Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025
From Innate Pharma SA
Via Business Wire
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit
Via Benzinga
Innate Pharma Announces €15M Investment by Sanofi
From Innate Pharma SA
Via Business Wire
Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company
From Innate Pharma SA
Via Business Wire
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
From Innate Pharma SA
Via Business Wire
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
From Innate Pharma SA
Via Business Wire
Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
From Innate Pharma SA
Via Business Wire
Innate Pharma Reports Full Year 2024 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Earnings Scheduled For March 27, 2025
Via Benzinga
Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
From Innate Pharma SA
Via Business Wire
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
From Innate Pharma SA
Via Business Wire

Frequently Asked Questions

Is Innate Pharma S.A. - American Depositary Shares publicly traded?
Yes, Innate Pharma S.A. - American Depositary Shares is publicly traded.
What exchange does Innate Pharma S.A. - American Depositary Shares trade on?
Innate Pharma S.A. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Innate Pharma S.A. - American Depositary Shares?
The ticker symbol for Innate Pharma S.A. - American Depositary Shares is IPHA on the Nasdaq Stock Market
What is the current price of Innate Pharma S.A. - American Depositary Shares?
The current price of Innate Pharma S.A. - American Depositary Shares is 1.790
When was Innate Pharma S.A. - American Depositary Shares last traded?
The last trade of Innate Pharma S.A. - American Depositary Shares was at 07/07/25 02:48 PM ET
What is the market capitalization of Innate Pharma S.A. - American Depositary Shares?
The market capitalization of Innate Pharma S.A. - American Depositary Shares is 141.39M
How many shares of Innate Pharma S.A. - American Depositary Shares are outstanding?
Innate Pharma S.A. - American Depositary Shares has 141M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.